Literature DB >> 26714848

Modeling changes in glucose and glycerol rates of appearance when true basal rates of appearance cannot be readily determined.

Laura Pyle1, Bryan C Bergman2, Kristen J Nadeau3, Melanie Cree-Green4.   

Abstract

Advancing diabetes care requires accurate physiological assessments. Hyperinsulinemic clamps with stable isotope tracers can simultaneously measure insulin's ability to suppress lipolysis and hepatic glucose release. Traditionally, these methods require an assessment of basal glucose and glycerol rate of appearance (Ra). Basal Ra is challenging to measure in insulin-dependent diabetes, where exogenous insulin required to maintain normoglycemia can raise peripheral insulin concentrations sufficiently to suppress basal Ra. Thus we identified two alternative statistical approaches to describe changes in glucose and glycerol Ra that are less reliant on basal assessments. Sixteen youths (4 type 1 diabetic, 4 type 2 diabetic, 4 lean controls, and 4 obese nondiabetic) underwent a four-phase ("basal" and 10, 16, and 80 mU·m(2)·min(-1)) hyperinsulinemic euglycemic clamp with glucose and glycerol tracers. Glucose and glycerol Ra were calculated per phase. A statistical method, the standard two-stage (STS) algorithm, was applied to the individual log insulin vs. Ra curves to calculate a single predicted Ra value. A population-based mixed-effects model (MEM) compared the group average Ra with log insulin curves and described individual deviations from group means and was used to calculate individual predicted Ra. Both models were applied to the participant data, and predicted Ras at the mean insulin concentration per phase (10 for glycerol, 16 for glucose) were calculated, with good agreement between observed and predicted values. In our data set, the MEM was better able to detect group differences. Both STS and MEM can model lipolysis and endogenous glucose release in insulin-dependent states when basal Ra cannot be accurately measured.
Copyright © 2016 the American Physiological Society.

Entities:  

Keywords:  diabetes; insulin resistance; modeling; stable isotope tracers

Mesh:

Substances:

Year:  2015        PMID: 26714848      PMCID: PMC4773652          DOI: 10.1152/ajpendo.00368.2015

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  31 in total

1.  Population approaches to estimate minimal model indexes of insulin sensitivity and glucose effectiveness using full and reduced sampling schedules.

Authors:  Kevin M Krudys; Steven E Kahn; Paolo Vicini
Journal:  Am J Physiol Endocrinol Metab       Date:  2006-10       Impact factor: 4.310

2.  Characterization of insulin secretion and resistance in type 2 diabetes of adolescents.

Authors:  Céline Druet; Nadia Tubiana-Rufi; Didier Chevenne; Odile Rigal; Michel Polak; Claire Levy-Marchal
Journal:  J Clin Endocrinol Metab       Date:  2005-11-15       Impact factor: 5.958

3.  Hepatic glucose and amino acid metabolism in diabetes.

Authors:  J Wahren; P Felig; E Cerasi; R Luft
Journal:  Isr J Med Sci       Date:  1972-06

4.  Relationship of glycerol uptake to plasma glycerol concentration in the normal dog.

Authors:  B Winkler; R Steele; N Altszuler
Journal:  Am J Physiol       Date:  1969-01

Review 5.  Insulin sensitivity and complications in type 1 diabetes: New insights.

Authors:  Petter Bjornstad; Janet K Snell-Bergeon; Kristen J Nadeau; David M Maahs
Journal:  World J Diabetes       Date:  2015-02-15

6.  Association of insulin sensitivity to lipids across the lifespan in people with Type 1 diabetes.

Authors:  D M Maahs; K Nadeau; J K Snell-Bergeon; I Schauer; B Bergman; N A West; M Rewers; S R Daniels; L G Ogden; R F Hamman; D Dabelea
Journal:  Diabet Med       Date:  2011-02       Impact factor: 4.359

7.  Response to glucose infusion in humans: role of changes in insulin concentration.

Authors:  R R Wolfe; J H Shaw; F Jahoor; D N Herndon; M H Wolfe
Journal:  Am J Physiol       Date:  1986-03

8.  Regulation of endogenous glucose production by glucose per se is impaired in type 2 diabetes mellitus.

Authors:  M Mevorach; A Giacca; Y Aharon; M Hawkins; H Shamoon; L Rossetti
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

9.  Strong association between insulin resistance in liver and skeletal muscle in non-diabetic subjects.

Authors:  M A Abdul-Ghani; M Matsuda; R A DeFronzo
Journal:  Diabet Med       Date:  2008-11       Impact factor: 4.359

10.  Hyperglycemia per se (insulin and glucagon withdrawn) can inhibit hepatic glucose production in man.

Authors:  J E Liljenquist; G L Mueller; A D Cherrington; J M Perry; D Rabinowitz
Journal:  J Clin Endocrinol Metab       Date:  1979-01       Impact factor: 5.958

View more
  9 in total

1.  Metformin Improves Peripheral Insulin Sensitivity in Youth With Type 1 Diabetes.

Authors:  Melanie Cree-Green; Bryan C Bergman; Eda Cengiz; Larry A Fox; Tamara S Hannon; Kellee Miller; Brandon Nathan; Laura Pyle; Darcy Kahn; Michael Tansey; Eileen Tichy; Eva Tsalikian; Ingrid Libman; Kristen J Nadeau
Journal:  J Clin Endocrinol Metab       Date:  2019-08-01       Impact factor: 5.958

2.  Advances in stable isotope tracer methodology part 1: hepatic metabolism via isotopomer analysis and postprandial lipolysis modeling.

Authors:  Cecilia Diniz Behn; Eunsook S Jin; Kate Bubar; Craig Malloy; Elizabeth J Parks; Melanie Cree-Green
Journal:  J Investig Med       Date:  2019-09-24       Impact factor: 2.895

3.  Youth with type 2 diabetes have hepatic, peripheral, and adipose insulin resistance.

Authors:  Melanie Cree-Green; Pattara Wiromrat; Jacob J Stuppy; Jessica Thurston; Bryan C Bergman; Amy D Baumgartner; Samantha Bacon; Ann Scherzinger; Laura Pyle; Kristen J Nadeau
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-12-18       Impact factor: 4.310

4.  Youth With Type 1 Diabetes Have Adipose, Hepatic, and Peripheral Insulin Resistance.

Authors:  Melanie Cree-Green; Jacob J Stuppy; Jessica Thurston; Bryan C Bergman; Gregory V Coe; Amy D Baumgartner; Samantha Bacon; Ann Scherzinger; Laura Pyle; Kristen J Nadeau
Journal:  J Clin Endocrinol Metab       Date:  2018-10-01       Impact factor: 5.958

5.  Methods for quantifying adipose tissue insulin resistance in overweight/obese humans.

Authors:  K W Ter Horst; K A van Galen; P W Gilijamse; A V Hartstra; P F de Groot; F M van der Valk; M T Ackermans; M Nieuwdorp; J A Romijn; M J Serlie
Journal:  Int J Obes (Lond)       Date:  2017-05-03       Impact factor: 5.095

6.  Nonalcoholic fatty liver disease in obese adolescent females is associated with multi-tissue insulin resistance and visceral adiposity markers.

Authors:  Melanie Cree-Green; Sonalee Ravi; Anne-Marie Carreau; Rachel Sewell; Amy Baumgartner; Gregory Coe; Bryan C Bergman; Ann Scherzinger; Thomas Jensen; Laura Pyle; Kristen J Nadeau
Journal:  Metabol Open       Date:  2019-06-08

7.  Muscle Insulin Resistance in Youth with Obesity and Normoglycemia is Associated with Altered Fat Metabolism.

Authors:  Melanie Cree-Green; Pattara Wiromrat; Jacob J Stuppy; Jessica Thurston; Bryan C Bergman; Amy D Baumgartner; Samantha Bacon; Ann Scherzinger; Laura Pyle; Kristen J Nadeau
Journal:  Obesity (Silver Spring)       Date:  2019-10-28       Impact factor: 5.002

8.  Insulin Resistance, Hyperinsulinemia, and Mitochondria Dysfunction in Nonobese Girls With Polycystic Ovarian Syndrome.

Authors:  Melanie Cree-Green; Haseeb Rahat; Bradley R Newcomer; Bryan C Bergman; Mark S Brown; Gregory V Coe; Lindsey Newnes; Yesenia Garcia-Reyes; Samantha Bacon; Jessica E Thurston; Laura Pyle; Ann Scherzinger; Kristen J Nadeau
Journal:  J Endocr Soc       Date:  2017-06-01

9.  Metabolite Profile of Treatment-Naive Metabolic Syndrome Subjects in Relation to Cardiovascular Disease Risk.

Authors:  Moritz V Warmbrunn; Annefleur M Koopen; Nicolien C de Clercq; Pieter F de Groot; Ruud S Kootte; Kristien E C Bouter; Kasper W Ter Horst; Annick V Hartstra; Mireille J Serlie; Mariette T Ackermans; Maarten R Soeters; Daniel H van Raalte; Mark Davids; Max Nieuwdorp; Albert K Groen
Journal:  Metabolites       Date:  2021-04-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.